VivoSeq
Other

Hfpef

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

HFpEF is an early-stage landscape with 0 programs across 4 companies. The most active players are Salubris Biotherapeutics Inc, Novartis, United Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Salubris Biotherapeutics Inc

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalUnited Therapeutics logo

United Therapeutics

0 programs

PreclinicalT

Tenax Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Recruiting3 · 30%
Withdrawn1 · 10%
Terminated1 · 10%
Enrolling by invitation1 · 10%

Clinical Trials

Trial Activity

10 trials

Matching Perfusion and Metabolic Activity in HFpEF
Recruiting·UUniversity of Pennsylvania·Phase 2·NCT04913805·53 enrolled
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Recruiting·CCytokinetics·Phase 2·NCT06793371·60 enrolled
Use of SGLT2i in noHCM With HFpEF
Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06401343·94 enrolled
Enhancing the Natriuretic Peptide System in HFpEF
Enrolling by invitation·—·Phase 1/2·NCT05279742·60 enrolled
Cilostazol for HFpEF
Completed·UUniversity of Minnesota·Phase 2·NCT05126836·25 enrolled
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
Completed·Novartis logoNovartis·Phase 3·NCT03988634·467 enrolled
Chronotropic Incompetence in Patients With HFpEF
Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT02524145·40 enrolled
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Completed·TTenax Therapeutics, Inc.·Phase 2·NCT03624010·20 enrolled
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
Terminated·United Therapeutics logoUnited Therapeutics·Phase 3·NCT03043651·48 enrolled
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
Withdrawn·SSalubris Biotherapeutics Inc·Phase 1·NCT05322616

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)